Treatment of MHC-I low human SCLC and neuroblastoma lines with VTP50469 increased IFN-γ-induced cell surface MHC-I, with the degree of induction mirroring the effects of EZH2 inhibitor (EZH2i) EPZ-011989 (Fig. 4a & Extended Data Fig. 5c/d). This evidence concerns the gene EZH2 and small cell lung carcinoma.